Clinical Edge Journal Scan

Women at higher risk for CRC death after adenoma removal


 

Key clinical point : Women who underwent adenoma removal appear to be at a higher risk for colorectal cancer (CRC) incidence and CRC-related deaths, highlighting the need for sex-specific surveillance after adenoma removal.

Major finding : Compared with general population, CRC incidence was higher in women (standardized incidence ratios [SIR], 1.64; 95% CI, 1.54-1.74) than in men (SIR, 1.12; 95% CI, 1.05-1.19) who had adenomas removed. CRC mortality increased in women (standardized incidence-based mortality ratios [SMR], 1.13; 95% CI, 1.02-1.26) and reduced in men (SMR, 0.79; 95% CI, 0.71-0.89) who underwent adenoma removal compared with general population.

Study details: Findings are from a cohort study of 40,293 individuals who had their adenomas removed.

Disclosures: This work was supported by grants from Norwegian Research Council and Norwegian Cancer Society. The authors declared no conflict of interests.

Source: Jodal HC et al. Aliment Pharmacol Ther. 2021 Oct 30. doi: 10.1111/apt.16686 .

Recommended Reading

Dogs show potential as medical detectives in breast cancer
MDedge Hematology and Oncology
Severe COVID two times higher for cancer patients
MDedge Hematology and Oncology
A single flexible sigmoidoscopy shows strong protective effect for CRC incidence and mortality
MDedge Hematology and Oncology
Simultaneous colectomy and HAIP placement safe in liver metastases of colon carcinoma
MDedge Hematology and Oncology
Young age tied with higher risk for relapse in high-risk stage III CRC
MDedge Hematology and Oncology
Higher intake of preserved vegetables and colorectal polyps: What is the link?
MDedge Hematology and Oncology
Preoperative SCRT with subsequent CAPOX and camrelizumab shows promise in locally advanced rectal cancer
MDedge Hematology and Oncology
Complications and outcomes of different management pathways of CRC and synchronous liver metastases
MDedge Hematology and Oncology
Immune checkpoint inhibitors and regorafenib combo shows promising efficacy in MSS CRC
MDedge Hematology and Oncology
Post-CRT sarcopenia predicts worse outcomes in locally advanced rectal cancer
MDedge Hematology and Oncology